$1.68 Billion is the total value of Sofinnova Investments, Inc.'s 69 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 61.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Natera | $308,568,000 | +37.8% | 3,100,560 | 0.0% | 18.37% | +10.6% | |
| KRTX | Karuna Therapeutics, Inc. | $198,348,000 | +31.4% | 1,952,441 | 0.0% | 11.81% | +5.5% | |
| ASND | Ascendis Pharma A/Sadr | $185,105,000 | +8.1% | 1,109,874 | 0.0% | 11.02% | -13.2% | |
| YMAB | Y-mAbs Therapeutics, Inc | $108,639,000 | +29.0% | 2,194,278 | 0.0% | 6.47% | +3.5% | |
| UTHR | Buy | United Therapeutics Corp | $52,808,000 | +62.9% | 347,901 | +8.4% | 3.14% | +30.8% |
| CMPI | Checkmate Pharmaceuticals Inc | $52,622,000 | +26.8% | 3,606,707 | 0.0% | 3.13% | +1.8% | |
| AZN | New | AstraZeneca PLCadr | $42,122,000 | – | 842,600 | +100.0% | 2.51% | – |
| INZY | Inozyme Pharma, Inc. | $41,864,000 | -21.5% | 2,028,308 | 0.0% | 2.49% | -37.0% | |
| AMGN | Buy | Amgen Inc | $37,859,000 | +33.5% | 164,663 | +47.5% | 2.25% | +7.1% |
| JAZZ | Buy | Jazz Pharmaceuticals PLC | $35,141,000 | +89.2% | 212,911 | +63.4% | 2.09% | +51.9% |
| XLV | New | Health Care Select Sector SPDRput | $34,032,000 | – | 300,000 | +100.0% | 2.03% | – |
| GRTX | Galera Therapeutics, Inc | $31,546,000 | +13.2% | 3,083,712 | 0.0% | 1.88% | -9.1% | |
| ABBV | Sell | Abbvie Inc | $31,459,000 | +5.2% | 293,596 | -14.0% | 1.87% | -15.5% |
| AKUS | Buy | Akouos, Incadr | $30,044,000 | -13.3% | 1,515,074 | +0.0% | 1.79% | -30.4% |
| New | Nextcure, Inc | $29,123,000 | – | 2,671,856 | +100.0% | 1.73% | – | |
| ITCI | Buy | Intra-Cellular Therapies Inc | $26,972,000 | +108.7% | 848,162 | +68.4% | 1.61% | +67.6% |
| IWM | New | iShares Russell 2000 ETFput | $25,488,000 | – | 130,000 | +100.0% | 1.52% | – |
| NCNA | Nucana Biomed Ltdadr | $25,144,000 | -13.2% | 5,599,999 | 0.0% | 1.50% | -30.3% | |
| MRUS | Merus N.V. | $22,983,000 | +46.1% | 1,311,039 | 0.0% | 1.37% | +17.2% | |
| PTCT | Sell | PTC Therapeutics Inc | $19,315,000 | +2.0% | 316,478 | -21.9% | 1.15% | -18.1% |
| RETA | Buy | Reata Pharmaceuticals Inc | $18,412,000 | +175.4% | 148,937 | +117.1% | 1.10% | +121.0% |
| ATHA | Athira Pharma, Inc. | $17,439,000 | +85.5% | 509,168 | 0.0% | 1.04% | +48.9% | |
| OTIC | Buy | Otonomy Inc | $16,956,000 | +98.3% | 2,620,668 | +24.1% | 1.01% | +59.1% |
| HZNP | New | Horizon Therapeutics PLC | $15,609,000 | – | 213,390 | +100.0% | 0.93% | – |
| New | Protagonist Therapeutics Inc | $14,614,000 | – | 724,904 | +100.0% | 0.87% | – | |
| BMRN | Sell | Biomarin Pharmaceutical Inc | $14,429,000 | -26.7% | 164,545 | -36.4% | 0.86% | -41.1% |
| ACRS | Aclaris Therapeutics | $12,368,000 | +151.7% | 1,911,573 | 0.0% | 0.74% | +102.2% | |
| RGNX | Buy | Regenxbio Inc | $12,298,000 | +650.8% | 271,114 | +355.6% | 0.73% | +505.0% |
| GWPH | Buy | GW Pharmaceuticals PLCadr | $11,629,000 | +44.0% | 100,762 | +21.5% | 0.69% | +15.5% |
| Nucana Biomed Ltdordinary shares | $10,776,000 | -13.2% | 2,400,000 | 0.0% | 0.64% | -30.3% | ||
| CYTK | Buy | Cytokinetics Inc | $10,564,000 | +39.7% | 508,394 | +45.5% | 0.63% | +12.1% |
| MGNX | New | MacroGenics Inc | $10,488,000 | – | 458,807 | +100.0% | 0.62% | – |
| INSM | Sell | Insmed Inc | $10,309,000 | -47.9% | 309,662 | -49.7% | 0.61% | -58.1% |
| TCRR | Buy | TCR2 Therapeutics Inc | $10,322,000 | +193.6% | 333,707 | +92.9% | 0.61% | +135.2% |
| OBSV | ObsEva SA | $9,879,000 | -16.1% | 4,749,623 | 0.0% | 0.59% | -32.6% | |
| ARNA | Buy | Arena Pharmaceuticals Inc | $9,325,000 | +41.5% | 121,373 | +37.7% | 0.56% | +13.5% |
| SRPT | New | Sarepta Therapeutics Inc | $8,840,000 | – | 51,848 | +100.0% | 0.53% | – |
| ACAD | Buy | ACADIA Pharmaceuticals Inc | $8,801,000 | +335.3% | 164,625 | +236.0% | 0.52% | +249.3% |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $8,365,000 | +207.0% | 1,122,800 | +41.6% | 0.50% | +146.5% |
| SNDX | New | Syndax Pharmaceuticals Inc | $8,293,000 | – | 372,909 | +100.0% | 0.49% | – |
| MIRM | Buy | Mirum Pharmaceuticals Inc | $7,944,000 | +28.3% | 454,974 | +41.6% | 0.47% | +3.1% |
| CHRS | Coherus BioSciences | $7,553,000 | -5.2% | 434,555 | 0.0% | 0.45% | -23.9% | |
| CCXI | Buy | ChemoCentryx Inc | $7,010,000 | +57.5% | 113,213 | +39.4% | 0.42% | +26.4% |
| JNCE | New | Jounce Therapeutics Inc | $6,477,000 | – | 925,280 | +100.0% | 0.39% | – |
| PBYI | Buy | Puma Biotechnology Inc | $6,460,000 | +34.5% | 629,650 | +32.3% | 0.38% | +8.1% |
| LLY | Sell | Eli Lilly and Co | $6,232,000 | -70.4% | 36,909 | -74.1% | 0.37% | -76.3% |
| AMRN | Amarin Corpadr | $5,724,000 | +16.2% | 1,170,584 | 0.0% | 0.34% | -6.6% | |
| ALGS | New | Aligos Therapeutics Inc | $5,283,000 | – | 191,061 | +100.0% | 0.31% | – |
| RCUS | New | Arcus Biosciences Inc | $4,836,000 | – | 186,278 | +100.0% | 0.29% | – |
| XLRN | Sell | Acceleron Pharma Inc | $4,694,000 | -29.9% | 36,688 | -38.4% | 0.28% | -43.9% |
| IOVA | New | Iovance Biotherapeutics Incput | $4,640,000 | – | 100,000 | +100.0% | 0.28% | – |
| New | Aptose Biosciences Inc | $4,297,000 | – | 981,135 | +100.0% | 0.26% | – | |
| IGMS | New | IGM Biosciences Inc | $3,985,000 | – | 45,131 | +100.0% | 0.24% | – |
| KURA | Sell | Kura Oncology Inc | $3,941,000 | -42.9% | 120,677 | -46.4% | 0.24% | -54.1% |
| TGTX | Sell | TG Therapeutics Inc | $3,406,000 | -49.2% | 65,474 | -73.9% | 0.20% | -59.2% |
| New | Marinus Pharmaceuticals Inc | $3,343,000 | – | 274,027 | +100.0% | 0.20% | – | |
| IMTX | Sell | Immatics NV | $3,016,000 | -12.7% | 279,532 | -14.1% | 0.18% | -29.7% |
| CALA | Buy | Calithera Biosciences Inc | $2,457,000 | +44.4% | 500,326 | +1.4% | 0.15% | +15.9% |
| CALA | New | Calithera Biosciences Incput | $1,964,000 | – | 400,000 | +100.0% | 0.12% | – |
| ZGNX | New | Zogenix Inc | $1,791,000 | – | 89,579 | +100.0% | 0.11% | – |
| SYBX | Synlogic Inc. | $1,242,000 | +7.0% | 574,972 | 0.0% | 0.07% | -14.0% | |
| FATE | Sell | Fate Therapeutics Inc | $1,227,000 | -25.8% | 13,497 | -67.4% | 0.07% | -40.7% |
| KDMN | Sell | Kadmon Holdings Inc | $950,000 | -61.5% | 228,893 | -63.7% | 0.06% | -68.9% |
| CALA | New | Calithera Biosciences Inccall | $860,000 | – | 175,000 | +100.0% | 0.05% | – |
| REPL | New | Replimune Group Inc | $763,000 | – | 20,000 | +100.0% | 0.04% | – |
| LQDA | Sell | Liquidia Corp | $436,000 | -87.0% | 147,744 | -78.3% | 0.03% | -89.5% |
| PDSB | PDS Biotechnology Corporation | $305,000 | -8.1% | 142,635 | 0.0% | 0.02% | -28.0% | |
| BCAB | New | Bioatla Inc | $102,000 | – | 3,000 | +100.0% | 0.01% | – |
| Exit | Kadmon Holdings Incwarrant | $0 | – | -240,091 | -100.0% | -0.01% | – | |
| SVRA | Exit | Savara Inc | $0 | – | -375,591 | -100.0% | -0.03% | – |
| ETTX | Exit | Entasis Therapeutics Holdings Inc. | $0 | – | -1,012,408 | -100.0% | -0.15% | – |
| CGEN | Exit | Compugen Ltd | $0 | – | -146,592 | -100.0% | -0.18% | – |
| FIXX | Exit | Homology Medicines Inc | $0 | – | -238,015 | -100.0% | -0.19% | – |
| Exit | Moderna Inccall | $0 | – | -50,000 | -100.0% | -0.26% | – | |
| AGTC | Exit | Applied Genetic Technologies Corp | $0 | – | -825,071 | -100.0% | -0.30% | – |
| KNSA | Exit | Kiniksa Pharmaceuticals, Ltd | $0 | – | -276,628 | -100.0% | -0.31% | – |
| CHMA | Exit | Chiasma | $0 | – | -1,047,354 | -100.0% | -0.33% | – |
| Exit | Novocure Ltdcall | $0 | – | -50,000 | -100.0% | -0.41% | – | |
| Exit | Reata Pharmaceuticals Incput | $0 | – | -60,000 | -100.0% | -0.43% | – | |
| OVID | Exit | Ovid Therapeutics Inc | $0 | – | -1,097,621 | -100.0% | -0.47% | – |
| MYOK | Exit | MyoKardia Inc | $0 | – | -48,998 | -100.0% | -0.50% | – |
| SUPN | Exit | Supernus Pharmaceuticals Inc | $0 | – | -330,295 | -100.0% | -0.51% | – |
| PTGX | Exit | Protagonist Therapeutics Inc | $0 | – | -357,769 | -100.0% | -0.52% | – |
| Exit | Cytokinetics Incput | $0 | – | -325,000 | -100.0% | -0.52% | – | |
| ZYME | Exit | Zymeworks Inc | $0 | – | -151,902 | -100.0% | -0.52% | – |
| Exit | Marinus Pharmaceuticals Inccall | $0 | – | -175,000 | -100.0% | -0.67% | – | |
| MRK | Exit | Merck & Co Inc | $0 | – | -190,559 | -100.0% | -1.17% | – |
| NXTC | Exit | Nextcure, Inc | $0 | – | -2,671,856 | -100.0% | -1.74% | – |
| Exit | Amgen Inccall | $0 | – | -59,500 | -100.0% | -3.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.